ClinicalTrials.gg
RecruitingNCT06953089Updated Oct 29, 2026

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

A Phase 2 interventional study of DB-1311/BNT324 and BNT327 in Solid Tumors, sponsored by DualityBio Inc.. Recruiting at 37 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by DualityBio Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 29, 2026Enrollment updatedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China — 171 open to participants now, 205 under way, 25 of them phase 3. Squamous Cell Carcinoma of Head and Neck · China.

Planned enrollment
6th of 265
750 · median 68
Started
2025
with 36 others
Phase 2
139 of 290
86 open now
Primary completion
2030-06
later than 193 of 204 live
Registered
204th of 290
by date

Among the 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China, this one is the 6th largest by planned enrollment of the 265 interventional ones that give a count, is one of 37 that started in 2025, is one of 139 in phase 2, reaches primary completion later than 193 of the 204 other live ones, and was the 204th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

171 of the 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China are open now. Recruiting first, the newest first:

166 more — sign in →

All 171 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China, or all of them as a file.
02

Study summary

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

Read the detailed description

This is a phase II, multicenter, open-label, two-part trial designed to evaluate the safety and preliminary efficacy of DB-1311 in combination with BNT327 or DB-1311 in combination with DB-1305 in targeted participants.

Participants with recurrent, progressive as well as advanced, metastatic hepatocellular carcinoma (HCC), cervical cancer (CC), melanoma, head and neck squamous cell carcinoma (HNSCC), platinum-resistant ovarian cancer (PROC), non-small cell lung cancer (NSCLC), platinum-sensitive ovarian cancer (PSOC), pancreatic ductal carcinoma (PDAC), breast cancer, colorectal cancer (CRC), or metastatic castration resistant prostate cancer (mCRPC) are eligible to participate in the trial.

03

Conditions studied

  • Solid Tumors

Keywords

  • B7-H3
  • PD-L1/VEGF-A
  • TROP2 (Trophoblast cell surface antigen 2)
  • ADC (antibody-drug conjugate)
  • HNSCC (head and neck squamous cell carcinoma)
  • HCC (hepatocellular carcinoma)
  • Melanoma
  • NSCLC(non-small cell lung cancer)
  • OC (ovarian cancer)
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adults aged ≥ 18 years or acceptable age according to local regulations at the time of voluntarily signing .
  • At least one as assessed by the Investigator according to v1.1 criteria.
  • Has a of ≥ 3 months.
  • Has an (ECOG) performance status (PS) of 0-1
  • Has adequate organ function within 7 days prior to enrollment/randomization,
  • Has adequate treatment prior to the first dose of trial treatment.

    • For HCC patients: Histological/cytological confirmed diagnosis of HCC or clinically confirmed diagnosis of HCC; Has a class A liver score.
    • For CC patients: Has persistent, recurrent or CC with squamous cell, adenocarcinoma, or adenosquamous histology
    • For Melanoma patients: or cytologically confirmed diagnosis of unresectable Stage III or metastatic/stage IV melanoma.
    • For PROC patients (Part 1, Cohort 1A): Participants must have a confirmed diagnosis of OC, primary peritoneal cancer, or fallopian tube cancer, all of which with high-grade serous histology. Patients must have platinum-resistant disease.
    • For HNSCC patients: Histologically or cytologically confirmed recurrent (recurrent disease that is not amendable to curative treatment with local/ or systemic therapies)/ (disseminated) HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies.
    • For NSCLC patients: Pathologically documented Stage IIIB or IIIC NSCLC not amenable for radical surgery or definitive chemoradiation or Stage IV NSQ NSCLC. Not harboring an EGFR-sensitizing mutation or ALK gene rearrangements or other onco-driver gene mutations
    • For PSOC (Part 2 Arm 6 only): Must have PSOC, defined as radiographically documented disease recurrence or progression occurring >6 months after completion of the last dose of platinum-based chemotherapy.
    • For PDAC (Part 2 Arm 7 only): Participants with advanced/unresectable metastatic PDAC without AGA who have progressed after only one prior line of standard systemic treatments (2L PDAC without AGA), or participants with AGA who have progressed on or after at least one and a maximum of two prior lines of standard systemic treatment (2L-3L PDAC with AGA).
    • For breast cancer (Part 2 Arm 8 only):

      • HR+/-low or HR+/HER2-ultralow or HR+/HER2-negative BC participants: Pathologically or cytologically documented HR-positive unresectable or metastatic BC with HER2-low, HER2-ultralow or HER2-negative expression.
      • Triple negative breast cancer (TNBC): Pathologically or cytologically documented unresectable or metastatic TNBC
    • For mCRC (Part 2 Arm 9 only): Participants with advanced/unresectable mCRC without AGA who have progressed after only one prior line of standard systemic treatment (2L mCRC without AGA), or participants with AGA who have progressed on or after at least one and a maximum of two prior lines of standard systemic treatment (2L-3L mCRC with AGA).
    • For mCRPC (Part 2 Arm 10 only): Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate and mCRPC

Key Exclusion Criteria:

  • 1. Prior treatment with B7H3 targeted therapy.
  • Prior treatment with antibody-drug conjugate with topoisomerase inhibitor.
  • Is a candidate to locoregional treatment with potential to induce complete or near complete response and prolonged tumor control, per investigator's assessment.
  • Has an uncontrolled concomitant or intercurrent illness, that in the opinion of the investigator, contra-indicates trial participation, limits compliance with trial procedures or substantially increases the risk of incurring AEs.
  • Has uncontrolled or significant cardiovascular disease. Has clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy.
  • Has a history of (non-infectious) ILD/pneumonitis.
  • Any , connective tissue or inflammatory disorders.
  • Has spinal cord compression or clinically active central nervous system (CNS) metastases.
  • Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline.
  • Other protocol defined inclusion and exclusion criteria apply.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
750 participants (estimated)

Study arms

  • Experimental
    Part 1 Cohort 1A, DB-1311/BNT324+ BNT327 combination therapy

    Escalating combination dose levels of DB-1311/BNT324 and BNT327 to define RP2D (Recommended Phase 2 Dose) and RP2D-1 in target population.

    Drug: DB-1311/BNT324 · Drug: BNT327

  • Experimental
    Part 1 Cohort 1B, DB-1311/BNT324+ BNT327 combination therapy

    Escalating combination dose levels of DB-1311/BNT324 and BNT327 to define RP2D and RP2D-1 in target population.

    Drug: DB-1311/BNT324 · Drug: BNT327

  • Experimental
    Part 1 Cohort 2, DB-1311/BNT324+ DB-1305 /BNT325 combination therapy

    Escalating combination dose levels of DB-1311/BNT324 and DB-1305/BNT325 to define RP2D and RP2D-1 in target population.

    Drug: DB-1311/BNT324 · Drug: DB-1305/BNT325

  • Experimental
    Part 2 Arm 1: RP2D of DB-1311/BNT324 + BNT327

    In participants with unresectable advanced/metastatic HCC

    Drug: DB-1311/BNT324 · Drug: BNT327

  • Experimental
    Part 2 Arm 2: RP2D of DB-1311/BNT324 + BNT327

    In participants with unresectable advanced/ metastatic CC

    Drug: DB-1311/BNT324 · Drug: BNT327

  • Experimental
    Part2 Arm 3:RP2D of DB-1311/BNT324 + BNT327

    In participants with unresectable advanced/metastatic melanoma

    Drug: DB-1311/BNT324 · Drug: BNT327

  • Experimental
    Part 2 Arm 4: RP2D of DB-1311/BNT324 + BNT327

    In participants with recurrent/metastatic HNSCC

    Drug: DB-1311/BNT324 · Drug: BNT327

  • Experimental
    Part 2 Arm 5: RP2D of DB-1311/BNT324 +DB-1305/BNT325 and RP2D-1 of DB-1311/BNT324 +DB-1305/BNT325

    In participants with advanced/unresectable metastatic NSCLC

    Drug: DB-1311/BNT324 · Drug: DB-1305/BNT325

  • Experimental
    Part 2 Arm 6: RP2D of DB-1311/BNT324 + BNT327

    In participants with unresectable advanced/metastatic PSOC

    Drug: DB-1311/BNT324 · Drug: BNT327

  • Experimental
    Part 2 Arm 7: RP2D of DB-1311/BNT324 + BNT327

    In participants with unresectable advanced/metastatic PDAC

    Drug: DB-1311/BNT324 · Drug: BNT327

  • Experimental
    Part 2 Arm 8: RP2D of DB-1311/BNT324 + BNT327

    In participants with unresectable advanced/metastatic breast cancer

    Drug: DB-1311/BNT324 · Drug: BNT327

  • Experimental
    Part 2 Arm 9: RP2D of DB-1311/BNT324 + BNT327

    In participants with unresectable advanced/metastatic CRC

    Drug: DB-1311/BNT324 · Drug: BNT327

  • Experimental
    Part 2 Arm 10: RP2D of DB-1311/BNT324 + BNT327

    In participants with unresectable advanced/metastatic mCRPC

    Drug: DB-1311/BNT324 · Drug: BNT327

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Number of participants with Dose Limiting Toxicities (DLTs).

    Time frame: During the DLT evaluation period, i.e., the time of initiation of the first dose of investigational medicinal product (IMP) up to 21 days

  2. Part 1: Treatment-emergent adverse events (TEAEs) and treatment-emergent serious AE (TESAEs)

    Time frame: up to follow up period, e.g. up to 72 months.

  3. Part 2: Objective response rate (ORR), defined as the proportion of participants in whom a confirmed Complete response (CR) or PR is observed as best overall response by arm and dose level. (Arm 1-9).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  4. ORR, defined as the proportion of participants in whom a confirmed CR or PR is observed as best overall response (per PCWG3-modified RECIST v1.1 as assessed by investigator) (Arm 10).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

Secondary outcomes

  1. Part 1: ORR, defined as the proportion of participants in whom a confirmed CR or PR is observed as best overall response (per RECIST 1.1 based on the investigator's assessment).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  2. Part 1 and 2: Duration of response (DoR) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  3. Part 1 and 2: Overall survival (OS)

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  4. Part 1 and 2: Disease-control rate (DCR) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  5. Part 1 and 2: Time to response (TTR) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  6. Part 1 and 2: Progression-free survival (PFS) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  7. Part 1: Cancer antigen 125 (CA-125) response rate assessed per Gynecological Cancer Intergroup (GCIG) criteria in participants with platinum-resistant ovarian cancer (PROC).

    Time frame: From the time of initiation of the first dose of IMP to end of Part 1

  8. Part 1 and 2: Cancer antigen 125 (CA-125) response rate assessed per Gynecological Cancer Intergroup (GCIG) criteria in participants with PROC.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  9. Part 2: Prostate-specific antigen (PSA)-based endpoints PSA50 response rate in participants with mCRPC (Arm 10).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  10. Part 2: Prostate-specific antigen (PSA)-based endpoints PSA90 response rate in participants with mCRPC (Arm 10).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  11. Part 2: Prostate-specific antigen (PSA)-based endpoints time to PSA progression in participants with mCRPC (Arm 10).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  12. Part 2: Prostate-specific antigen (PSA)-based endpoints duration of PSA response in participants with mCRPC (Arm 10).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  13. Part 2:Treatment-emergent adverse events (TEAEs) and treatment-emergent serious AE (TESAEs)

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  14. Part 1 and 2: Maximum observed concentration (Cmax) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with BNT327.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  15. Part 1 and 2: Maximum observed concentration (Cmax) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with DB-1305/BNT325.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  16. Part 1 and 2: Time to reach maximum observed concentration (Tmax) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with BNT327.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  17. Part 1 and 2: Time to reach maximum observed concentration (Tmax) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with DB-1305/BNT325.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  18. Part 1 and 2: Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with BNT327.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  19. Part 1 and 2: Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with DB-1305/BNT325.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  20. Part 1 and 2: Terminal elimination half-life (t1/2) of DB-1311/BNT324 total ADC, total antibody and unconjugated P1021 in combination with BNT327.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  21. Part 1 and 2: Terminal elimination half-life (t1/2) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with DB-1305/BNT325.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  22. Part 1 and 2: Anti-drug antibody (ADA) prevalence: the proportion of participants who are ADA positive at any point in time (at baseline and post-baseline).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

  23. Part 1 and Part 2: ADA incidence: the proportion of participants having treatment-emergent ADA.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

07

Study locations

37 of 37 sites recruiting
  • USA06-0
    Los Angeles, California 90025, United States
    Recruiting
  • USA16-0
    Los Angeles, California 90025, United States
    Recruiting
  • USA01-0
    Wheat Ridge, Colorado 80033, United States
    Recruiting
  • USA08-0
    Florida City, Florida 99208, United States
    Recruiting
  • USA10-0
    Atlanta, Georgia 30318, United States
    Recruiting
  • USA11-0
    Bethesda, Maryland 20817, United States
    Recruiting
  • USA14-0
    Lincoln, Nebraska 68506, United States
    Recruiting
  • USA04-0
    New York, New York 10032, United States
    Recruiting
  • USA15-0
    Portland, Oregon 97239, United States
    Recruiting
  • USA03-0
    Charleston, South Carolina 29425, United States
    Recruiting
  • USA13-0
    Anderson, Texas 46011, United States
    Recruiting
  • USA12-0
    Houston, Texas 77030, United States
    Recruiting
  • USA05-0
    Virginia Beach, Virginia 22031, United States
    Recruiting
  • USA09-0
    Puyallup, Washington 98373, United States
    Recruiting
  • USA07-0
    Spokane, Washington 99208, United States
    Recruiting
  • AUS07-0
    North Sydney, New South Wales 2060, Australia
    Recruiting
  • AUS06-0
    Benowa, Queensland 4217, Australia
    Recruiting
  • AUS04-0
    Birtinya, Queensland 4575, Australia
    Recruiting
  • AUS05-0
    Adelaide, South Australia 5000, Australia
    Recruiting
  • CHN02-0
    Beijing, Beijing Municipality 100021, China
    Recruiting
  • CHN13-0
    Beijing, Beijing Municipality 100032, China
    Recruiting
  • CHN23-0
    Beijing, Beijing Municipality 100142, China
    Recruiting
  • CHN17-0
    Dongguan, Guangdong 523000, China
    Recruiting
  • CHN06-0
    Henan, Henan 450008, China
    Recruiting
  • CHN12-0
    Xinxiang, Henan 453100, China
    Recruiting
  • CHN04-0
    Hubei, Hubei 430014, China
    Recruiting
  • CHN26-0
    Wuhan, Hubei 00000, China
    Recruiting
  • CHN34-0
    Wuhan, Hubei 430079, China
    Recruiting
  • CHN11-0
    Changsha, Hunan 410013, China
    Recruiting
  • CHN16-0
    Xuzhou, Jiangsu 221000, China
    Recruiting
  • CHN35-0
    Shenyang, Liaoning 110042, China
    Recruiting
  • CHN25-0
    Xi'an, Shaanxi 710061, China
    Recruiting
  • CHN04-0
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
  • CHN01-0
    Shanghai, Shanghai Municipality 200120, China
    Recruiting
  • CHN24-0
    Chengdu, Sichuan 610041, China
    Recruiting
  • TWN01-0
    Taipei, Taipei 0, Taiwan
    Recruiting
  • TWN02-0
    Taipei, Taipei 23561, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2030, 59 months after the start.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 59 months is above that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
May 1, 2025
StartActual
Jul 18, 2025
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2030
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
450→750
Oct 29, 2026
Eligibility
2 inclusion criteria removed; 6 criteria edited, 5 added
What changed in the criteria
  • AddedKey Inclusion Criteria:
  • EditedFor CC patients: Has persistent, recurrent or metastatic cervical cancerCC with squamous cell, adenocarcinoma, or adenosquamous histology
  • EditedFor Melanoma patients: Histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic/stage IV melanoma.
  • EditedFor PROC patients (Part 1, Cohort A1A): Participants must have a confirmed diagnosis of OC, primary peritoneal cancer, or fallopian tube cancer, all of which with high-grade serous histology. Patients must have platinum-resistant disease.
  • EditedFor PSOC (Part 2 Arm 6 only): Must have PSOC, defined as radiographically documented disease recurrence or progression occurring >6 months after completion of the last dose of platinum-based chemotherapy.
  • AddedFor PDAC (Part 2 Arm 7 only): Participants with advanced/unresectable metastatic PDAC without AGA who have progressed after only one prior line of standard systemic treatments (2L PDAC without AGA), or participants with AGA who have progressed on or after at least one and a maximum of two prior lines of standard systemic treatment (2L-3L PDAC with AGA).
  • AddedFor breast cancer (Part 2 Arm 8 only):
  • ChangedBefore For mCRC: Participants who have metastatic CRC and have relapsed or progressed after 1 prior line of systemic treatment including a fluoropyrimidine plus oxaliplatin with or without anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) or anti-epidermal growth factor receptor mAb therapy, as clinically indicated, or have relapsed or progressed after 2 lines of therapy if the participant has received targeted therapyNow For mCRC (Part 2 Arm 9 only): Participants with advanced/unresectable mCRC without AGA who have progressed after only one prior line of standard systemic treatment (2L mCRC without AGA), or participants with AGA who have progressed on or after at least one and a maximum of two prior lines of standard systemic treatment (2L-3L mCRC with AGA).
  • EditedFor mCRPC (Part 2 Arm 10 only): Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate and mCRPC
  • AddedKey Exclusion Criteria:
  • AddedOther protocol defined inclusion and exclusion criteria apply.
Inclusion criteria
  • RemovedFor PDAC: Participants must have histologically or cytologically confirmed metastatic PDAC., who have progressed after at least one prior line of standard systemic treatment ((≥2L PDAC).)
  • RemovedFor breast cancer:
Oct 29, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedPart 2: Objective response rate (ORR), defined as the proportion of participants in whom a confirmed Complete response (CR) or PR is observed as best overall response (per RECIST 1.1 based on the investigator's assessment)by arm and dose level. (Arm 1-9).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
  • ChangedBefore Part 2: Treatment-emergent adverse events (TEAEs) and treatment-emergent serious AE (TESAEs) [By arm and dose level]Now ORR, defined as the proportion of participants in whom a confirmed CR or PR is observed as best overall response (per PCWG3-modified RECIST v1.1 as assessed by investigator) (Arm 10).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Oct 29, 2026
Secondary outcomes
5 edited, 4 added
What changed in the outcomes
  • EditedPart 1 and 2: Duration of response (DoR) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
  • EditedPart 1 and 2: Disease-control rate (DCR) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
  • EditedPart 1 and 2: Time to response (TTR) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
  • EditedPart 1 and 2: Progression-free survival (PFS) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
  • EditedPart 1 and 2: Cancer antigen 125 (CA-125) response rate assessed per Gynecological Cancer Intergroup (GCIG) criteria in participants with PROC.Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
  • AddedPart 2: Prostate-specific antigen (PSA)-based endpoints PSA50 response rate in participants with mCRPC (Arm 10).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
  • AddedPart 2: Prostate-specific antigen (PSA)-based endpoints PSA90 response rate in participants with mCRPC (Arm 10).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
  • AddedPart 2: Prostate-specific antigen (PSA)-based endpoints time to PSA progression in participants with mCRPC (Arm 10).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
  • AddedPart 2: Prostate-specific antigen (PSA)-based endpoints duration of PSA response in participants with mCRPC (Arm 10).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Enrollment 450→750
    Eligibility 2 inclusion criteria removed; 6 criteria edited, 5 added
    What changed in the criteria
    • AddedKey Inclusion Criteria:
    • EditedFor CC patients: Has persistent, recurrent or metastatic cervical cancerCC with squamous cell, adenocarcinoma, or adenosquamous histology
    • EditedFor Melanoma patients: Histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic/stage IV melanoma.
    • EditedFor PROC patients (Part 1, Cohort A1A): Participants must have a confirmed diagnosis of OC, primary peritoneal cancer, or fallopian tube cancer, all of which with high-grade serous histology. Patients must have platinum-resistant disease.
    • EditedFor PSOC (Part 2 Arm 6 only): Must have PSOC, defined as radiographically documented disease recurrence or progression occurring >6 months after completion of the last dose of platinum-based chemotherapy.
    • AddedFor PDAC (Part 2 Arm 7 only): Participants with advanced/unresectable metastatic PDAC without AGA who have progressed after only one prior line of standard systemic treatments (2L PDAC without AGA), or participants with AGA who have progressed on or after at least one and a maximum of two prior lines of standard systemic treatment (2L-3L PDAC with AGA).
    • AddedFor breast cancer (Part 2 Arm 8 only):
    • ChangedBefore For mCRC: Participants who have metastatic CRC and have relapsed or progressed after 1 prior line of systemic treatment including a fluoropyrimidine plus oxaliplatin with or without anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) or anti-epidermal growth factor receptor mAb therapy, as clinically indicated, or have relapsed or progressed after 2 lines of therapy if the participant has received targeted therapyNow For mCRC (Part 2 Arm 9 only): Participants with advanced/unresectable mCRC without AGA who have progressed after only one prior line of standard systemic treatment (2L mCRC without AGA), or participants with AGA who have progressed on or after at least one and a maximum of two prior lines of standard systemic treatment (2L-3L mCRC with AGA).
    • EditedFor mCRPC (Part 2 Arm 10 only): Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate and mCRPC
    • AddedKey Exclusion Criteria:
    • AddedOther protocol defined inclusion and exclusion criteria apply.
    Inclusion criteria
    • RemovedFor PDAC: Participants must have histologically or cytologically confirmed metastatic PDAC., who have progressed after at least one prior line of standard systemic treatment ((≥2L PDAC).)
    • RemovedFor breast cancer:
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedPart 2: Objective response rate (ORR), defined as the proportion of participants in whom a confirmed Complete response (CR) or PR is observed as best overall response (per RECIST 1.1 based on the investigator's assessment)by arm and dose level. (Arm 1-9).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
    • ChangedBefore Part 2: Treatment-emergent adverse events (TEAEs) and treatment-emergent serious AE (TESAEs) [By arm and dose level]Now ORR, defined as the proportion of participants in whom a confirmed CR or PR is observed as best overall response (per PCWG3-modified RECIST v1.1 as assessed by investigator) (Arm 10).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
    Secondary outcomes 5 edited, 4 added
    What changed in the outcomes
    • EditedPart 1 and 2: Duration of response (DoR) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
    • EditedPart 1 and 2: Disease-control rate (DCR) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
    • EditedPart 1 and 2: Time to response (TTR) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
    • EditedPart 1 and 2: Progression-free survival (PFS) per RECIST 1.1 (Arm 1-9) and per PCWG3-modified RECIST v1.1 (Arm 10) based on the investigator's assessment.Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
    • EditedPart 1 and 2: Cancer antigen 125 (CA-125) response rate assessed per Gynecological Cancer Intergroup (GCIG) criteria in participants with PROC.Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
    • AddedPart 2: Prostate-specific antigen (PSA)-based endpoints PSA50 response rate in participants with mCRPC (Arm 10).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
    • AddedPart 2: Prostate-specific antigen (PSA)-based endpoints PSA90 response rate in participants with mCRPC (Arm 10).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
    • AddedPart 2: Prostate-specific antigen (PSA)-based endpoints time to PSA progression in participants with mCRPC (Arm 10).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
    • AddedPart 2: Prostate-specific antigen (PSA)-based endpoints duration of PSA response in participants with mCRPC (Arm 10).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06953089
Lead sponsor
DualityBio Inc.
Collaborators
BioNTech SE
Responsible party
Sponsor
First posted
May 1, 2025
Start date
Jul 18, 2025
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Oct 29, 2026

Study contacts

Jay Ma
Contact
jay.ma@dualitybiologics.com
540-808-3925
Qiaoli Jiang
Contact
qiaoli.jiang@dualitybiologics.com
+86-15210642683

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion